[HTML][HTML] Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus …
Vancomycin-resistant Staphylococcus aureus (VRSA), Vancomycin-intermediate S. aureus
(VISA) and heterogeneous VISA (hVISA) are subject to vancomycin treatment failure. The …
(VISA) and heterogeneous VISA (hVISA) are subject to vancomycin treatment failure. The …
Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical …
A Shariati, M Dadashi, MT Moghadam… - Scientific …, 2020 - europepmc.org
Vancomycin-resistant Staphylococcus aureus (VRSA), Vancomycin-intermediate S. aureus
(VISA) and heterogeneous VISA (hVISA) are subject to vancomycin treatment failure. The …
(VISA) and heterogeneous VISA (hVISA) are subject to vancomycin treatment failure. The …
Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical …
A Shariati, M Dadashi, MT Moghadam… - Scientific …, 2020 - search.ebscohost.com
Vancomycin-resistant Staphylococcus aureus (VRSA), Vancomycin-intermediate S. aureus
(VISA) and heterogeneous VISA (hVISA) are subject to vancomycin treatment failure. The …
(VISA) and heterogeneous VISA (hVISA) are subject to vancomycin treatment failure. The …
[HTML][HTML] Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus …
A Shariati, M Dadashi, MT Moghadam… - Scientific …, 2020 - ncbi.nlm.nih.gov
Vancomycin-resistant Staphylococcus aureus (VRSA), Vancomycin-intermediate S. aureus
(VISA) and heterogeneous VISA (hVISA) are subject to vancomycin treatment failure. The …
(VISA) and heterogeneous VISA (hVISA) are subject to vancomycin treatment failure. The …
Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical …
A Shariati, M Dadashi, MT Moghadam, A van Belkum… - 2020 - cabidigitallibrary.org
Vancomycin-resistant Staphylococcus aureus (VRSA), Vancomycin-intermediate S. aureus
(VISA) and heterogeneous VISA (hVISA) are subject to vancomycin treatment failure. The …
(VISA) and heterogeneous VISA (hVISA) are subject to vancomycin treatment failure. The …
Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical …
A Shariati, M Dadashi, MT Moghadam… - Scientific …, 2020 - pubmed.ncbi.nlm.nih.gov
Vancomycin-resistant Staphylococcus aureus (VRSA), Vancomycin-intermediate S. aureus
(VISA) and heterogeneous VISA (hVISA) are subject to vancomycin treatment failure. The …
(VISA) and heterogeneous VISA (hVISA) are subject to vancomycin treatment failure. The …
Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical …
A Shariati, M Dadashi, MT Moghadam… - Scientific …, 2020 - ui.adsabs.harvard.edu
Vancomycin-resistant Staphylococcus aureus (VRSA), Vancomycin-intermediate S. aureus
(VISA) and heterogeneous VISA (hVISA) are subject to vancomycin treatment failure. The …
(VISA) and heterogeneous VISA (hVISA) are subject to vancomycin treatment failure. The …
Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical …
A Shariati, M Dadashi, MT Moghadam… - Scientific …, 2020 - europepmc.org
Vancomycin-resistant Staphylococcus aureus (VRSA), Vancomycin-intermediate S. aureus
(VISA) and heterogeneous VISA (hVISA) are subject to vancomycin treatment failure. The …
(VISA) and heterogeneous VISA (hVISA) are subject to vancomycin treatment failure. The …